



PATENT  
Attorney Docket No. 056291-5189

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: <b>Lanna LI</b>	)	Confirmation No.: <b>6704</b>
	)	
Application No.: <b>10/518,007</b>	)	Group Art Unit: <b>1621</b>
	)	
Filed: <b>December 14, 2004</b>	)	Examiner: <b>Witherspoon</b>
	)	
For: <b>ORTHO-SUBSTITUTED BENZOIC ACID</b>	)	Date: <b>July 9, 2007</b>
<b>DERIVATIVES FOR THE TREATMENT OF</b>	)	
<b>INSULIN RESISTANCE</b>	)	/

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Window, **Mail Stop Amendment**  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.**

**§ 1.97(b) ACCOMPANYING A REQUEST FOR CONTINUED EXAMINATION**

**Citation of Technically Related U.S. Patent Applications**

The Examiner's attention is directed to the following table of technically related U.S. patents or applications of Applicant's assignee, which table is an update of the Table previously submitted in this application on February 28, 2007, on which the new entries are **highlighted in bold**:

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Lindstedt-Alstermark et al	10/499,042 March 28, 2005		WO 03/051826 June 26, 2003
Lindstedt-Alstermark et al.	10/499,261 March 4, 2005		WO 03/051821 June 26, 2003
Lindstedt-Alstermark et al	10/499,378 September 7, 2004		WO 03/051822 June 26, 2003

Inventor	U.S. Serial No. Filing Date	U.S. Patent No. Issue Date	PCT Publication No. PCT Publication Date
Lindstedt-Alstermark et al.	<b>10/499,893</b> <b>June 21, 2004</b>		<b>WO 2004/056748</b> <b>July 8, 2004</b>
Li	10/518,819 December 20, 2004		WO 2004/000295 December 31, 2003
Li	10/519,376 December 20, 2004		WO 2004/000294 December 31, 2003
Ragnar et al.	<b>10/560,127</b> <b>June 16, 2004</b>		<b>WO 2004/110985</b> <b>December 23, 2004</b>
Aurell et al.	<b>10/560,657</b> <b>June 16, 2004</b>		<b>WO 2004/110984</b> <b>December 23, 2004</b>
Lindstedt-Alstermark et al.	<b>10/561,126</b> <b>December 18, 2005</b>		<b>WO 2004/113282</b> <b>December 29, 2004</b>
Lindstedt-Alstermark et al.	<b>10/561,161</b> <b>December 16, 2005</b>		<b>WO 2004/113285</b> <b>December 29, 2004</b>
Lindstedt-Alstermark	<b>10/561,168</b> <b>December 16, 2005</b>		<b>WO 2004/113276</b> <b>December 29, 2004</b>
Ahlqvist et al.	<b>10/561,170</b> <b>December 16, 2005</b>		<b>WO 2004/113284</b> <b>December 29, 2004</b>
Ahlqvist et al.	<b>10/561,222</b> <b>December 19, 2005</b>		<b>WO 2004/113283</b> <b>December 29, 2004</b>
Lindstedt-Alstermark et al.	<b>11/026,806</b> <b>December 30, 2004</b>		<b>WO 03/051821</b> <b>June 26, 2003</b>
Starke et al.	<b>10/220,877</b> <b>March 5, 2001</b>	<b>6,906,058</b> <b>June 14, 2005</b>	<b>WO 01/66533</b> <b>September 13, 2001</b>
Starke et al.	<b>10/399,336</b> <b>Sept. 16, 2003</b>		<b>WO 02/32428</b> <b>April 25, 2002</b>
Starke et al.	<b>10/451,262</b> <b>June 20, 2003</b>	<b>7,192,945</b> <b>March 20, 2007</b>	<b>WO 02/50051</b> <b>June 27, 2002</b>
Starke et al.	<b>10/488,540</b> <b>July 23, 2004</b>	<b>7,192,946</b> <b>March 20, 2007</b>	<b>WO 03/020710</b> <b>March 13, 2003</b>
Starke et al.	<b>10/488,870</b> <b>October 7, 2004</b>	<b>7,132,416</b> <b>November 7, 2006</b>	<b>WO 03/022286</b> <b>March 20, 2003</b>
Starke et al.	<b>10/489,009</b> <b>October 8, 2004</b>	<b>7,125,864</b> <b>October 24, 2006</b>	<b>WO 03/022825</b> <b>March 20, 2003</b>
Starke et al.	<b>10/489,010</b> <b>October 21, 2004</b>	<b>7,226,943</b> <b>June 5, 2007</b>	<b>WO 03/022830</b> <b>March 20, 2003</b>
Starke et al.	<b>10/511,984</b> <b>October 21, 2004</b>	<b>7,238,684</b> <b>July 3, 2007</b>	<b>WO 03/091232</b> <b>November 6, 2003</b>
Starke et al.	<b>10/518,010</b> <b>December 14, 2004</b>	<b>7,192,947</b> <b>March 20, 2007</b>	<b>WO 03/106482</b> <b>December 24, 2003</b>

Each US Patent **highlighted in bold** on the above table is listed on the attached form PTO-1449, and each corresponding published PCT application **highlighted in bold** on the above

table is listed on the attached form PTO-1449 and a copy is provided herewith. Except for the Starke et al. applications, all applications relate to PPAR antagonists. The Starke et al. applications relate to IBAT inhibitors and are included herein because they disclose combinations of the specifically claimed IBAT inhibitors with a PPAR antagonist. Consideration of each listed application is earnestly solicited.

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant petitions the Examiner to consider this Information Disclosure Statement and documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Information Disclosure Statement is being filed before the mailing of a first office action after the filing of a request for continued examination under §1.114. Accordingly, Applicants do not believe a fee is due for filing this Information Disclosure Statement.

With the exception of U.S. Patents, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." Applicant reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required,

including any required extension of time fees, or credit any overpayment to Deposit Account No.

50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR  
EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**



Date: **July 9, 2007**  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000


By:

---

Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

PTO Form 1449  
July 9, 2007Attorney Docket No.  
056291-5189Application No.  
10/518,007

Applicants: Lanna LI

Filing Date: December 14, 2004

Group Art Unit: 1621

**U.S. PATENT DOCUMENTS**

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	1	6,906,058	June 14, 2005	Starke et al.			
	2	7,125,864	October 24, 2006	Starke et al.			
	3	7,132,416	November 7, 2006	Starke et al.			
	4	7,192,945	March 20, 2007	Starke et al.			
	5	7,192,946	March 20, 2007	Starke et al.			
	6	7,192,947	March 20, 2007	Starke et al.			
	7	7,226,943	June 5, 2997	Starke et al.			
	8	7,238,684	July 3, 2007	Starke et al.			

**FOREIGN PATENT DOCUMENTS**

		Document No.	Date	Country	Class	Sub-Class	Translation
	9	WO 01/66533	September 13, 2001	WIPO			
	10	WO 02/32428	April 25, 2002	WIPO			
	11	WO 02/50051	June 27, 2002	WIPO			
	12	WO 03/020710	March 13, 2003	WIPO			
	13	WO 03/022286	March 20, 2003	WIPO			
	14	WO 03/022825	March 20, 2003	WIPO			
	15	WO 03/022830	March 20, 2003	WIPO			
	16	WO 03/051821	June 26, 2003	WIPO			
	17	WO 03/051822	June 26, 2003	WIPO			
	18	WO 03/051826	June 26, 2003	WIPO			
	19	WO 03/091232	November 6, 2003	WIPO			
	20	WO 03/106482	December 24, 2003	WIPO			
	21	WO 04/000294	December 31, 2003	WIPO			
	22	WO 04/000295	December 31, 2003	WIPO			
	23	WO 04/056748	June 8, 2004	WIPO			
	24	WO 04/110984	December 23, 2004	WIPO			
	25	WO 04/110985	December 23, 2004	WIPO			
	26	WO 04/113276	December 29, 2004	WIPO			
	27	WO 04/113282	December 29, 2004	WIPO			
	28	WO 04/113283	December 29, 2004	WIPO			
	29	WO 04/113284	December 29, 2004	WIPO			
	30	WO 04/113285	December 29, 2004	WIPO			

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)**


Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.